Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
Table 2
Characteristics and laboratory data of streptozotocin-induced diabetic apolipoprotein E-null mice assigned to the indicated treatments.
Control
Ipragliflozin
Alogliptin
Combination
Number
6
4
3
5
Final body weight (g)
23.7 ± 0.4
25.4 ± 0.8
25.2 ± 0.4
24.5 ± 0.4
Food intake (g/day)
4.3 ± 0.2
3.8 ± 0.2
4.5 ± 0.6
7.0 ± 0.3a,b,c
Water intake (mL/day)
13.7 ± 0.7
16.6 ± 1.1
13.7 ± 1.8
14.9 ± 0.7
SBP (mmHg)
122 ± 6
113 ± 5
123 ± 10
112 ± 2
Pulse (/min)
662 ± 14
675 ± 1
597 ± 6a,b
620 ± 13
Final body weight (g)
23.7 ± 0.4
25.4 ± 0.8
25.2 ± 0.4
24.5 ± 0.4
Glucose (mg/dL)
212 ± 33
285 ± 38
141 ± 24
192 ± 30
HbA1c (%)
8.5 ± 0.2
6.6 ± 0.3a
8.0 ± 0.9
6.1 ± 0.3a
Total-C (mg/dL)
467 ± 12
433 ± 16
475 ± 16
388 ± 33
HDL-C (mg/dL)
42 ± 4
52 ± 4
55 ± 3
47 ± 6
Triglyceride (mg/dL)
125 ± 22
161 ± 12
152 ± 22
140 ± 23
The values show mean ± SEM. a versus control; b versus ipragliflozin; c versus alogliptin.
